Ragas Dental College & Hospital commonly called "RDC Chennai", is a dental college located at the outskirts of Chennai, India. It is affiliated to The Tamil Nadu Dr. M.G.R. Medical University. It was founded by Dr. B.P. Rajan, a conservative dentist, in 1987 in Radhakrishnan Road, Chennai. Its first Dean was Dr. Vasanta Rao..
The search for new, biocompatible, and antimicrobially active root canal irrigants has led researchers to investigate various natural substances. While the therapeutic potential of Nigella sativa (N. sativa) in endodontics is not widely documented, its promising properties warrant further exploration. To evaluate and compare the antibacterial efficacy of 25
Neonatal hypoglycemia is the most common metabolic disorder in newborns and can lead to neurological damage if untreated. While intravenous dextrose is the standard treatment, it is invasive. Oral 40
Dental caries remains one of the most ubiquitous chronic diseases worldwide, affecting people across geographic, socioeconomic, and demographic boundaries. In response to this pervasive burden, the consensus statement; developed by a panel of experts in cariology, restorative dentistry and endodontics during the Symposium on Deep Caries Management Symposium at the 39th Indian Association of Conservative Dentistry and Endodontics National Conference, Jio Convention Centre, Mumbai, November 29, to December 3, 2024, synthesises contemporary understanding of carious pathogenesis with evidence-based clinical strategies. It is intended for dental practitioners managing deep caries in vital permanent teeth of all age groups, from adolescents to older adults. Recommendations are grounded in systematic reviews, high-quality clinical trials, and structured expert consensus, charting the paradigmatic evolution from traditional, invasive endodontic approaches toward biologically informed, minimally invasive care that prioritises tissue preservation and harnesses natural reparative processes. The guideline outlines diagnostic thresholds, risk-assessment tools, and operative protocols - such as selective caries excavation and vital pulp therapy - that optimise long-term outcomes while reducing adverse events. This consensus statement has been formulated according to the AGREE guidelines for reporting consensus-based recommendations, ensuring methodological rigour and transparency in development. It elucidates the complex interplay between microbiological, biochemical, and structural factors governing caries initiation and progression, while establishing evidence-based protocols for conservative management that optimize long-term therapeutic outcomes.
AIM:To assess the efficacy of topical rhEGF on healing outcomes at palatal soft-tissue donor sites. MATERIALS AND METHODS:This randomised, controlled clinical trial included 60 patients who required harvesting of palatal soft-tissue grafts. Out of two groups, the intervention group received rhEGF gel (60 μg/application for 5 days) and the comparator group received a placebo gel. Wound healing was assessed by wound area reduction and palatal early healing index (PEHI). Post-operative pain was assessed using the numerical rating scale (NRS; 0-10), including donor site complications. Measurements were recorded daily for the first 5 days and at 2, 4 and 8 weeks post-operatively. RESULTS:Fifty-five participants completed the trial, with dropouts in both groups (intervention [n = 3], control [n = 2]). The test group showed significantly faster healing, as evidenced by higher PEHI scores (p = 0.0011) and greater wound area reduction (p = 0.0057). Post-operative pain was reduced significantly in the rhEGF group, and pain was nearly absent from day 2 onwards (p = 0.0004). No adverse effects were reported in the intervention group, whereas three participants in the control group experienced prolonged post-operative pain. CONCLUSIONS:Topical rhEGF for 5 days significantly enhanced palatal donor site healing, reduced the wound area and alleviated post-operative pain.
This study aims to evaluate the efficacy of duloxetine in managing temporomandibular joint disorder (TMD), focusing on pain reduction and functional improvement. The research addresses the need for novel therapeutic agents due to the suboptimal efficacy and tolerability of existing treatments. A systematic review and Bayesian meta-analysis were conducted following PRISMA guidelines. A comprehensive search of MEDLINE (via PubMed), Web of Science, Scopus, Embase, and Google Scholar was performed up to February 2025. Eligibility criteria were defined using the PICOS framework: Population (TMD patients), Intervention (duloxetine), Comparator (placebo or other treatments), Outcomes (pain reduction, maximum mouth opening), and Study design (randomized controlled trials). Data synthesis employed Bayesian meta-analysis, and evidence quality was assessed using the GRADE framework. Five studies involving 203 participants met the inclusion criteria. Four evaluated duloxetine combined with TMJ arthrocentesis, while one compared duloxetine to a placebo. Combination therapy yielded significant pain reduction (pooled effect size = 1.42) and a consistent, though not statistically significant, improvement in maximum mouth opening. Bayesian analysis strongly supported pain reduction (BF10 = 44.197) but was inconclusive for functional improvement (BF10 = 0.783). The risk of bias ranged from moderate to high, with high-certainty evidence supporting the efficacy of combination therapy. Duloxetine, when combined with TMJ arthrocentesis, provides significant pain relief and potential functional benefits in TMD management. However, further large-scale, high-quality randomized trials are necessary to confirm these findings.
